FDA approves Polivy in combination with R-CHP for people with certain types of 1L DLBCL April 27, 2023
IMBRUVICA’s U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications to be voluntarily withdrawn April 12, 2023
Positive CHMP Opinion for Breyanzi for R/R Large B-cell Lymphoma After One Prior Therapy April 6, 2023
Yescarta® Demonstrates Statistically Significant OS Improvement for Initial Treatment of R/R Large B-cell Lymphoma March 31, 2023
Calquence granted first regulatory approval in China for adults with previously treated mantle cell lymphoma March 31, 2023
FDA Advisory Committee Votes In Favour of the Clinical Benefit of Polivy Combination For People With 1L DLBCL March 15, 2023
FDA Clearance of IND Application for Phase 1/2 Clinical Trial (Starlight-1) of EB103, a CD19-Targeted ARTEMIS® T Cell Therapy, to Patients with B-Cell Lymphomas March 15, 2023
Refusal to File Letter issued from U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma February 22, 2023
FDA Approves Jaypirca™ (pirtobrutinib) for Adult Patients with R/R Mantle Cell Lymphoma After at Least Two Lines of Systemic Therapy, Including a BTKi February 8, 2023
IND cleared for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies February 1, 2023
FDA clears IND for Novel Bispecific CAR IMPT-314 to Treat Aggressive B-cell Lymphoma February 1, 2023
Complete Response Of The First Patient Treated In B-Cell Non-Hodgkin Lymphoma (B-NHL) Ph 1 Clinical Trial Of PMB-CT01 (BAFFR-CAR T Cells) announced January 4, 2023
FDA approved Lunsumio® (mosunetuzumab-axgb) for the treatment of adult patients with R/R follicular lymphoma January 4, 2023
Initial Data from the Ongoing Ph 2B VITALIZE Trial in Patients with r/r DLBCL announced December 19, 2022
Application in European Union Seeking Approval of IMBRUVICA (ibrutinib) for the Treatment of Patients with Untreated Mantle Cell Lymphoma withdrawn December 19, 2022
Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting announced December 13, 2022
